Skip to main content

Table 5 LOCF analysis

From: One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

Overall population (N = 140)

M0

M3

M6

M9

M12

Response rate ≥ 30%—n (%)

-

114 (81.4)

98 (70.0)

92 (65.7)

93 (66.4)

Response rate ≥ 50%—n (%)

-

74 (52.9)

70 (50.0)

65 (46.4)

65 (46.4)

Response rate ≥ 75%—n (%)

-

22 (15.7)

22 (15.7)

27 (19.3)

27 (19.3)

MHDs

22.5 ± 7.3

14.5 ± 9.6*

15.1 ± 9.7*

14.9 ± 9.9*

15.0 ± 10.0*

Change from BL

-

8.0 ± 7.1

7.5 ± 7.5

7.6 ± 8.3

7.5 ± 7.9

MMDs

19.6 ± 7.4

11.5 ± 8.5*

12.0 ± 8.6*

12.2 ± 8.9*

12.3 ± 9.0*

Change from BL

-

8.1 ± 5.9

7.6 ± 6.4

7.5 ± 6.7

7.5 ± 7.9

HIT

68.0 ± 6.0

59.3 ± 8.1*

58.5 ± 9.3*

58.4 ± 10.1*

58.6 ± 9.4*

Change from BL

-

8.8 ± 7.7

9.6 ± 8.9

9.6 ± 9.6

9.4 ± 8.8

  1. *Paired t-test with M0 <.001